PharmaBioSource provided transaction consulting services to Nycomed on the sale of its 155,200 SF Devon, Pennsylvania research and development facility to Merck & Co.

• Service: Transaction Consulting
• Sector: Life Sciences
• Sub-sector: R&D / Vaccines
• Engagement Type: Sell Side

PharmaBioSource provided transaction services to divest Nycomed’s small molecule imaging R&D lab facility to Merck & Co.  Merck acquired the facility near Philadelphia with plans to convert the chemistry laboratories into microbiology labs to support the testing of all of the company’s vaccine clinical trial samples.  Merck also installed a cryogenic freezer farm and vaccine sample stability storage area in
the facility.  The facility also housed a multi-function pilot plant that Merck also planned to utilize for drug discovery purposes.

PharmaBioSource’s services included a benchmark valuation, buyer target identification, creation of the confidential information memorandum (CIM), data room development and due diligence support.